Hangzhou, China

Guanglin Zhou

USPTO Granted Patents = 1 

Average Co-Inventor Count = 14.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Guanglin Zhou

Introduction

Guanglin Zhou is a notable inventor based in Hangzhou, China. He has made significant contributions to the field of pharmaceuticals through his innovative work. His research focuses on developing treatments for various diseases related to the dysregulation of kinases.

Latest Patents

Guanglin Zhou holds a patent for a process related to the manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide. This invention pertains to solid forms of certain N-(pyrimidinyloxy)acrylamide derivatives. These derivatives are useful in treating proliferation and immunological disorders, as well as other diseases linked to kinase dysregulation, including EGFR, Alk, and JAK kinases. The patent also provides methods for making these materials, their salts, polymorphs, and pharmaceutical compositions that include them.

Career Highlights

Guanglin Zhou is currently associated with Acea Therapeutics, Inc., where he continues to advance his research and development efforts. His work has the potential to impact the treatment of various conditions, including tumors, inflammatory diseases, autoimmune diseases, and more.

Collaborations

Guanglin Zhou collaborates with talented individuals such as Long Mao and Jia Liu. Their combined expertise contributes to the innovative environment at Acea Therapeutics, Inc.

Conclusion

Guanglin Zhou's contributions to the field of pharmaceuticals through his patent and collaborative efforts highlight his role as an influential inventor. His work aims to provide effective treatments for serious health conditions, showcasing the importance of innovation in medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…